

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Highly Specialised Technologies Evaluation

Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) ID1530

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Alexion Pharma UK (ravulizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Answers for aHUS • Contact a Family • Findacure • Genetic Alliance UK • Kidney Care UK • Kidney Research UK • Kids Kidney Research • Muslim Council of Britain National Children's Bureau • National Kidney Federation • South Asian Health Foundation • Specialised Healthcare Alliance • Thrombosis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Industries • Association of Renal Technologists • Association of Surgeons of Great Britain and Ireland • British Association for Paediatric Nephrology • British Association of Urological Nurses • British Association of Urological Surgeons • British Committee for Standards in Haematology 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association • Welsh Urological Society <p><u>Possible comparator companies</u></p> <p>None</p> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Kidney & Transplant • Genomics England

Provisional stakeholder list for the proposed highly specialised technologies evaluation of ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) ID1530

Issue Date: November 2019

© National Institute for Health and Care Excellence 2019. All rights reserved

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Geriatric Society • British Renal Society • British Society for Haematology • British Society for Human Genetics • British Transplantation Society • NHS Blood and Transplant • Rare Renal • Renal Association • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders • UK National Screening Committee • UK Primary Immunodeficiency Network • UK Renal Pharmacy Group • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • National Renal Complement Therapeutics Centre • NHS England 	<ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Provisional stakeholder list for the proposed highly specialised technologies evaluation of ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) ID1530

Issue Date: November 2019

© National Institute for Health and Care Excellence 2019. All rights reserved

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.